M2BIO is a division of MJ Medtech that aims to help take psilocybin-based medicine to the forefront by deploying solid medicine, by-products, and clinical research.
Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has a high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including depressed mood, anxiety disorders, obsessive-compulsive disorder, alcohol use disorder, and tobacco use disorder. M2BIO is currently doing an in-depth review of studies performed and their results in each of these conditions and evaluate the clinical potential for use.
Psilocybin has been a subject of preliminary research since the early 1960s, when the Harvard Psilocybin Project evaluated the potential therapeutic value of psilocybin for personality disorders. Beginning in the 2000s decade, research on anxiety disorders, major depression, and various addictions was conducted. Psilocybin has been tested for its potential for developing prescription drugs to treat drug dependence, anxiety or mood disorders. In 2018 the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for psilocybin-assisted therapy for treatment-resistant depression.